Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04966741 · ClinicalTrials.gov registry record · Phase 3
Setmelanotide in Pediatric Participants With Rare Genetic Diseases of Obesity
A Phase 3 study, sponsored by Rhythm Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 12
- Enrollment target
NCT04966741 is a Phase 3 study that has completed, run by Rhythm Pharmaceuticals. The registered enrollment target is 12 participants.
The verdict
NCT04966741, a Phase 3 study, has completed, sponsored by Rhythm Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 12 participants
- Enrollment target
Study Summary
This is a phase 3 open-label, clinical study to evaluate the efficacy, safety and tolerability of setmelanotide over 1 year of treatment, in pediatric participants aged 2 to \<6 years with obesity due to either biallelic variants of the pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1) or leptin receptor (LEPR) genes or Bardet-Biedl Syndrome (BBS).
Interventions
- DRUG Setmelanotide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2022-03-08 |
| Est. Completion | 2024-11-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04966741
The ClinicalTrials.gov registry entry for NCT04966741 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Rhythm Pharmaceuticals, which has 23 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Setmelanotide is the first listed.
NCT04966741 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04966741 about?
NCT04966741 is a clinical study titled "Setmelanotide in Pediatric Participants With Rare Genetic Diseases of Obesity". This is a phase 3 open-label, clinical study to evaluate the efficacy, safety and tolerability of setmelanotide over 1 year of treatment, in pediatric participants aged 2 to \<6 years with obesity due to either biallelic variants of the pro-opiomelanocortin (POMC), proprotein convertase subtilisin/k...
What is the current status of trial NCT04966741?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 12 participants. The study started on 2022-03-08. Estimated completion is 2024-11-08.
What interventions are being tested in trial NCT04966741?
The interventions under investigation include: Setmelanotide (DRUG).
Who is sponsoring clinical trial NCT04966741?
This trial is sponsored by Rhythm Pharmaceuticals, which has 23 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.